Supply / Manufacturing · Latin America · Announced 17 Nov 2026
Celltrion → Brazilian federal government
Celltrion won Brazil's federal government tender for its trastuzumab biosimilar Herzuma for a seventh straight year, becoming sole supplier of about 1 million vials through end-2027.
Parties: Celltrion (South Korea) → Brazilian federal government (public tender) (Brazil)
- Deal type
- Supply / Manufacturing
- Value
- Undisclosed
- Territory
- Brazil — federal public-sector trastuzumab supply (about 80% of the public trastuzumab market)
- Therapeutic area
- Oncology
- Asset
- Herzuma (trastuzumab)
- Announced
- 17 Nov 2026
Our analysis
Why this matters
Celltrion announced on 17 November 2026 that its Brazilian subsidiary won a Brazilian federal government tender for Herzuma, its biosimilar of trastuzumab used in breast and gastric cancer. Celltrion will be the sole supplier of about 1 million vials through the end of 2027. No contract value was disclosed. It is the seventh consecutive year Herzuma has won the federal tender; the first win came in 2020, the year after its Brazilian launch.
According to the company, the federal tender covers about 80% of Brazil's public trastuzumab market, and public and private channels split roughly 80/20. Celltrion cites IQVIA data putting Herzuma's share of Brazilian trastuzumab at about 50%.
The full analysis is free to read with a work email on this page.
Source: Korea Biomedical Review